{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:00:23Z","timestamp":1794276023881,"version":"4.9.0"},"reference-count":98,"publisher":"Pacini Editore","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Otorhinolaryngol Ital"],"DOI":"10.14639\/0392-100x-n1614","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T15:19:14Z","timestamp":1627053554000},"page":"1-16","source":"Crossref","is-referenced-by-count":72,"title":["Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology","Biologici nel trattamento della poliposi naso-sinusale severa non controllata: cambiamento nelle strategie terapeutiche. Consensus dei membri della Commissione SIO sui farmaci biologici in rinologia"],"prefix":"10.14639","volume":"42","author":[{"given":"Eugenio","family":"De Corso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bellocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Macchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malvezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pagella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiderio","family":"Passali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"20340","published-online":{"date-parts":[[2022,2]]},"reference":[{"key":"10.14639\/0392-100X-N1614_ref1","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020;58:1-464. https:\/\/doi.org\/10.4193\/Rhin20.600","DOI":"10.4193\/Rhin20.600"},{"key":"10.14639\/0392-100X-N1614_ref2","doi-asserted-by":"crossref","unstructured":"Divekar RD, Samant S, Rank MA, et al. Immunological profiling in chronic rhinosinusitis with nasal polyps reveals distinct VEGF and GM-CSF signatures during symptomatic exacerbations. Clin Exp Allergy 2015;45:767-778. https:\/\/doi.org\/10.1111\/cea.12463","DOI":"10.1111\/cea.12463"},{"key":"10.14639\/0392-100X-N1614_ref3","doi-asserted-by":"crossref","unstructured":"Rank MA, Hagan JB, Samant SA, et al. A proposed model to study immunologic changes during chronic rhinosinusitis exacerbations: data from a pilot study. Am J Rhinol Allergy 2013;27:98-101. https:\/\/doi.org\/10.2500\/ajra.2013.27.3850","DOI":"10.2500\/ajra.2013.27.3850"},{"key":"10.14639\/0392-100X-N1614_ref4","doi-asserted-by":"crossref","unstructured":"Hellings PW, Akdis CA, Bachert C, et al. EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology 2017;55:202-210. https:\/\/doi.org\/10.4193\/Rhin17.028","DOI":"10.4193\/Rhino17.028"},{"key":"10.14639\/0392-100X-N1614_ref5","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:1-12. https:\/\/doi.org\/10.4193\/Rhino50E2","DOI":"10.4193\/Rhino12.000"},{"key":"10.14639\/0392-100X-N1614_ref6","doi-asserted-by":"crossref","unstructured":"Bachert C, Bhattacharyya N, Desrosiers M, et al. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy 2021;14:127-134. https:\/\/doi.org\/10.2147\/JAA.S290424","DOI":"10.2147\/JAA.S290424"},{"key":"10.14639\/0392-100X-N1614_ref7","doi-asserted-by":"crossref","unstructured":"Vlaminck S, Acke F, Prokopakis E, et al. Surgery in nasal polyp patients: outcome after a minimum observation of 10 years. Am J Rhinol Allergy 2021;35:449-457. https:\/\/doi.org\/10.1177\/1945892420961964","DOI":"10.1177\/1945892420961964"},{"key":"10.14639\/0392-100X-N1614_ref8","doi-asserted-by":"crossref","unstructured":"Vanderhaegen T, Gengler I, Dendooven A, et al. Eosinophils in the field of nasal polyposis: towards a better understanding of biologic therapies. Clin Rev Allergy Immunol 2021 Jan 26. https:\/\/doi.org\/10.1007\/s12016-021-08844-7. Online ahead of print.","DOI":"10.1007\/s12016-021-08844-7"},{"key":"10.14639\/0392-100X-N1614_ref9","doi-asserted-by":"crossref","unstructured":"Peters AT, Han JK, Hellings P, et al. Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 2021;3:S2213-219800159-8. https:\/\/doi.org\/10.1016\/j.jaip.2021.01.031.","DOI":"10.1016\/j.jaip.2021.01.031"},{"key":"10.14639\/0392-100X-N1614_ref10","doi-asserted-by":"crossref","unstructured":"Stevens WW, Lee RJ, Schleimer RP, et al. Chronic rhinosinusitis pathogenesis. J Allergy Clin Immunol 2015;136:1442-1453. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.009","DOI":"10.1016\/j.jaci.2015.10.009"},{"key":"10.14639\/0392-100X-N1614_ref11","doi-asserted-by":"crossref","unstructured":"Mahdavinia M, Keshavarzian A, Tobin MC, et al. A comprehensive review of the nasal microbiome in chronic rhinosinusitis (CRS). Clin Exp Allergy 2016;46:21-41. https:\/\/doi.org\/10.1111\/cea.12666","DOI":"10.1111\/cea.12666"},{"key":"10.14639\/0392-100X-N1614_ref12","doi-asserted-by":"crossref","unstructured":"Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol 2017;24;12:331-357. https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100401","DOI":"10.1146\/annurev-pathol-052016-100401"},{"key":"10.14639\/0392-100X-N1614_ref13","doi-asserted-by":"crossref","unstructured":"Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic rhinosinusitis. role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med 2015;192:682-694. https:\/\/doi.org\/10.1164\/rccm.201412-2278OC","DOI":"10.1164\/rccm.201412-2278OC"},{"key":"10.14639\/0392-100X-N1614_ref14","doi-asserted-by":"crossref","unstructured":"Lee K, Tai J, Lee SH, et al. Advances in the knowledge of the underlying airway remodeling mechanisms in chronic rhinosinusitis based on the endotypes: a review. Int J Mol Sci 2021;22:910. https:\/\/doi.org\/10.3390\/ijms22020910","DOI":"10.3390\/ijms22020910"},{"key":"10.14639\/0392-100X-N1614_ref15","doi-asserted-by":"crossref","unstructured":"Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2013;131:1479-1490. https:\/\/doi.org\/10.1016\/j.jaci.2013.02.036","DOI":"10.1016\/j.jaci.2013.02.036"},{"key":"10.14639\/0392-100X-N1614_ref16","doi-asserted-by":"crossref","unstructured":"Wang M, Bu X, Luan G, et al. Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma. Clin Transl Allergy 2020;3:10-26. https:\/\/doi.org\/10.1186\/s13601-020-00332-z","DOI":"10.1186\/s13601-020-00332-z"},{"key":"10.14639\/0392-100X-N1614_ref17","doi-asserted-by":"crossref","unstructured":"Busse WW, Kraft M, Rabe KF, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J 2021 Feb 4;2003393. https:\/\/doi.org\/10.1183\/13993003.03393-2020. Online ahead of print.","DOI":"10.1183\/13993003.03393-2020"},{"key":"10.14639\/0392-100X-N1614_ref18","doi-asserted-by":"crossref","unstructured":"Bachert C, Gevaert P, Holtappels G, et al. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 2001;107:607-614. https:\/\/doi.org\/10.1067\/mai.2001.112374","DOI":"10.1067\/mai.2001.112374"},{"key":"10.14639\/0392-100X-N1614_ref19","doi-asserted-by":"crossref","unstructured":"Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol 2021;147:29-36. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.013","DOI":"10.1016\/j.jaci.2020.11.013"},{"key":"10.14639\/0392-100X-N1614_ref20","doi-asserted-by":"crossref","unstructured":"De Corso E, Baroni S, Romitelli F, et al. Nasal lavage CCL24 levels correlate with eosinophils trafficking and symptoms in chronic sino-nasal eosinophilic inflammation. Rhinology 2011;49:174-179. https:\/\/doi.org\/10.4193\/Rhino10.133","DOI":"10.4193\/Rhino10.133"},{"key":"10.14639\/0392-100X-N1614_ref21","doi-asserted-by":"crossref","unstructured":"De Corso E, Settimi S, Tricarico L, et al. Predictors of disease control after endoscopic sinus surgery plus long-term local corticosteroids in CRSwNP. Am J Rhinol Allergy 2021;35:77-85. https:\/\/doi.org\/10.1177\/1945892420936196","DOI":"10.1177\/1945892420936196"},{"key":"10.14639\/0392-100X-N1614_ref22","doi-asserted-by":"crossref","unstructured":"Gelardi M, De Candia N, Quaranta N, et al. The relevance of counseling in patients with nasal polyps. Acta Otorhinolaryngol Ital 2016; 36:326-327. https:\/\/doi.org\/10.14639\/0392-100X-1315","DOI":"10.14639\/0392-100X-1315"},{"key":"10.14639\/0392-100X-N1614_ref23","doi-asserted-by":"crossref","unstructured":"De Corso E, Battista M, Pandolfini M, et al. Role of inflammation in non-allergic rhinitis. Rhinology 2014;52:142-149. https:\/\/doi.org\/10.4193\/Rhino13.102","DOI":"10.4193\/Rhino13.102"},{"key":"10.14639\/0392-100X-N1614_ref24","doi-asserted-by":"crossref","unstructured":"Gallo S, Bandi F, Preti A, et al. Exploring the role of nasal cytology in chronic rhinosinusitis. Acta Otorhinolaryngol Ital 2020;40:368-376. https:\/\/doi.org\/10.14639\/0392-100X-N0711","DOI":"10.14639\/0392-100X-N0711"},{"key":"10.14639\/0392-100X-N1614_ref25","doi-asserted-by":"crossref","unstructured":"De Corso E, Baroni S, Battista M, et al. Nasal fluid release of eotaxin-3 and eotaxin-2 in persistent sinonasal eosinophilic inflammation. Int Forum Allergy Rhinol 2014;4:617-624. https:\/\/doi.org\/10.1002\/alr.21348","DOI":"10.1002\/alr.21348"},{"key":"10.14639\/0392-100X-N1614_ref26","doi-asserted-by":"crossref","unstructured":"De Corso E, Anzivino R, Galli J, et al. Antileukotrienes improve naso-ocular symptoms and biomarkers in patients with NARES and asthma. Laryngoscope 2019;129:551-557. https:\/\/doi.org\/10.1002\/lary.27576","DOI":"10.1002\/lary.27576"},{"key":"10.14639\/0392-100X-N1614_ref27","doi-asserted-by":"crossref","unstructured":"Unsal AA, Reyes C, Biddinger P, et al. Eosinophilic mucin: a predictor for disease severity in chronic rhinosinusitis. Am J Rhinol Allergy 2021;35:187-194. https:\/\/doi.org\/10.1177\/1945892420943828","DOI":"10.1177\/1945892420943828"},{"key":"10.14639\/0392-100X-N1614_ref28","doi-asserted-by":"crossref","unstructured":"Gelardi M, Iannuzzi L, De Giosa M, et al. Non-surgical management of chronic rhinosinusitis with nasal polyps based on clinical-cytological grading: a precision medicine-based approach. Acta Otorhinolaryngol Ital 2017;37:38-45. https:\/\/doi.org\/10.14639\/0392-100X-1417","DOI":"10.14639\/0392-100X-1417"},{"key":"10.14639\/0392-100X-N1614_ref29","doi-asserted-by":"crossref","unstructured":"De Corso E, Lucidi D, Cantone E, et al. Clinical evidence and biomarkers linking allergy and acute or chronic rhinosinusitis in children: a systematic review. Curr Allergy Asthma Rep 2020;20:68. https:\/\/doi.org\/10.1007\/s11882-020-00967-9.","DOI":"10.1007\/s11882-020-00967-9"},{"key":"10.14639\/0392-100X-N1614_ref30","doi-asserted-by":"crossref","unstructured":"Bandi F, Gallo S, Preti A, Mozzanica F, et al. Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients. Acta Otorhinolaryngol Ital 2020;40:435-443. https:\/\/doi.org\/10.14639\/0392-100X-N0716","DOI":"10.14639\/0392-100X-N0716"},{"key":"10.14639\/0392-100X-N1614_ref31","doi-asserted-by":"crossref","unstructured":"De Corso E, Lucidi D, Battista M, et al. Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end? Int Forum Allergy Rhinol 2017;7:861-867. https:\/\/doi.org\/10.1002\/alr.21979","DOI":"10.1002\/alr.21979"},{"key":"10.14639\/0392-100X-N1614_ref32","doi-asserted-by":"crossref","unstructured":"Ho J, Earls P, Harvey RJ. Systemic biomarkers of eosinophilic chronic rhinosinusitis. Curr Opin Allergy Clin Immunol 2020;20:23-29. https:\/\/doi.org\/10.1097\/ACI.0000000000000602","DOI":"10.1097\/ACI.0000000000000602"},{"key":"10.14639\/0392-100X-N1614_ref33","doi-asserted-by":"crossref","unstructured":"Posteraro B, Scarano E, La Sorda M, et al. Eosinophilic fungal rhinosinusitis due to the unusual pathogen Curvularia inaequalis. Mycoses 2010;53:84-88. http:\/\/doi.org\/10.1111\/j.1439-0507.2008.01671.x","DOI":"10.1111\/j.1439-0507.2008.01671.x"},{"key":"10.14639\/0392-100X-N1614_ref34","doi-asserted-by":"crossref","unstructured":"De Corso E, Baroni S, Lucidi D, et al. Nasal lavage levels of granulocyte-macrophage colony-stimulating factor and chronic nasal hypereosinophilia. Int Forum Allergy Rhinol 2015;5:557-562. https:\/\/doi.org\/10.1002\/alr.21519","DOI":"10.1002\/alr.21519"},{"key":"10.14639\/0392-100X-N1614_ref35","doi-asserted-by":"crossref","unstructured":"Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315:469-479. https:\/\/doi.org\/10.1001\/jama.2015.19330","DOI":"10.1001\/jama.2015.19330"},{"key":"10.14639\/0392-100X-N1614_ref36","doi-asserted-by":"crossref","unstructured":"Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013;131:110-6.e1. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.047","DOI":"10.1016\/j.jaci.2012.07.047"},{"key":"10.14639\/0392-100X-N1614_ref37","doi-asserted-by":"crossref","unstructured":"Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011;128:989-995.e1-8. https:\/\/doi.org\/10.1016\/j.jaci.2011.07.056","DOI":"10.1016\/j.jaci.2011.07.056"},{"key":"10.14639\/0392-100X-N1614_ref38","doi-asserted-by":"crossref","unstructured":"Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol 2017;140:1024-1031.e14. https:\/\/doi.org\/10.1016\/j.jaci.2017.05.044","DOI":"10.1016\/j.jaci.2017.05.044"},{"key":"10.14639\/0392-100X-N1614_ref39","doi-asserted-by":"crossref","unstructured":"Chitguppi C, Patel P, Gandler A, et al. Effect of benralizumab in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a case series. Am J Rhinol Allergy 2020;10:1945892420978351. https:\/\/doi.org\/10.1177\/1945892420978351","DOI":"10.1177\/1945892420978351"},{"key":"10.14639\/0392-100X-N1614_ref40","doi-asserted-by":"crossref","unstructured":"Lombardo N, Pelaia C, Ciriolo M, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol 2020;34:2058738420950851. https:\/\/doi.org\/10.1177\/2058738420950851","DOI":"10.1177\/2058738420950851"},{"key":"10.14639\/0392-100X-N1614_ref41","doi-asserted-by":"crossref","unstructured":"Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019;394:1638-1650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"10.14639\/0392-100X-N1614_ref42","doi-asserted-by":"crossref","unstructured":"Laidlaw TM, Bachert C, Amin N, et al. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol 2021;16:S1081-120600020-X. https:\/\/doi.org\/10.1016\/j.anai.2021.01.012","DOI":"10.1016\/j.anai.2021.01.012"},{"key":"10.14639\/0392-100X-N1614_ref43","doi-asserted-by":"crossref","unstructured":"Bachert C, Zinreich SJ, Hellings PW, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology 2020;58:10-17. https:\/\/doi.org\/10.4193\/Rhin18.282","DOI":"10.4193\/Rhin18.282"},{"key":"10.14639\/0392-100X-N1614_ref44","doi-asserted-by":"crossref","unstructured":"Kim J, Naclerio R. Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date. Ther Clin Risk Manag 2020;16:31-37. https:\/\/doi.org\/10.2147\/TCRM.S210648","DOI":"10.2147\/TCRM.S210648"},{"key":"10.14639\/0392-100X-N1614_ref45","doi-asserted-by":"crossref","unstructured":"Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders Am J Respir Crit Care Med 2001;164:S6-S11. https:\/\/doi.org\/10.1164\/ajrccm.164.supplement_1.2103025","DOI":"10.1164\/ajrccm.164.supplement_1.2103025"},{"key":"10.14639\/0392-100X-N1614_ref46","doi-asserted-by":"crossref","unstructured":"Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997;9:805-813. https:\/\/doi.org\/10.1016\/s0952-7915(97)80182-3","DOI":"10.1016\/S0952-7915(97)80182-3"},{"key":"10.14639\/0392-100X-N1614_ref47","doi-asserted-by":"crossref","unstructured":"Jardieu P. Anti-IgE therapy. Curr Opin Immunol 1995;7:779-82. https:\/\/doi.org\/10.1016\/0952-7915(95)80047-6","DOI":"10.1016\/0952-7915(95)80047-6"},{"key":"10.14639\/0392-100X-N1614_ref48","doi-asserted-by":"crossref","unstructured":"Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression J Allergy Clin Immunol 2003;112:1147-1154. https:\/\/doi.org\/10.1016\/j.jaci.2003.10.003","DOI":"10.1016\/j.jaci.2003.10.003"},{"key":"10.14639\/0392-100X-N1614_ref49","doi-asserted-by":"crossref","unstructured":"Scheerens H, Smith A, Li O, et al. Elevated IgE M1 prime transcripts in nasal tissues in patients with nasal polyps and asthma. J Allergy Clin Immunol 2019;143:805-807. https:\/\/doi.org\/10.1016\/j.jaci.2018.10.011","DOI":"10.1016\/j.jaci.2018.10.011"},{"key":"10.14639\/0392-100X-N1614_ref50","doi-asserted-by":"crossref","unstructured":"Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020;146:595-605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","DOI":"10.1016\/j.jaci.2020.05.032"},{"key":"10.14639\/0392-100X-N1614_ref51","doi-asserted-by":"crossref","unstructured":"Howarth P, Chupp G, Nelsen LM, et al. Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol 2020;145:1713-1715. https:\/\/doi.org\/10.1016\/j.jaci.2020.02.002","DOI":"10.1016\/j.jaci.2020.02.002"},{"key":"10.14639\/0392-100X-N1614_ref52","doi-asserted-by":"crossref","unstructured":"Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add- on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017;5:390-400. https:\/\/doi.org\/10.1016\/S2213-2600(17)30125-X","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"10.14639\/0392-100X-N1614_ref53","doi-asserted-by":"crossref","unstructured":"Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-1207. https:\/\/doi.org\/10.1056\/NEJMoa1403290","DOI":"10.1056\/NEJMoa1403290"},{"key":"10.14639\/0392-100X-N1614_ref54","unstructured":"Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021;S2213-260000097. https\/\/doi.org\/10.1016\/S2213-2600(21)00097-7"},{"key":"10.14639\/0392-100X-N1614_ref55","doi-asserted-by":"crossref","unstructured":"Hopkins C, Bachert C, Fokkens W, et al. Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study. Eur Respir J 2020;56:4616. https:\/\/doi.org\/10.1183\/13993003","DOI":"10.1183\/13993003.congress-2020.4616"},{"key":"10.14639\/0392-100X-N1614_ref56","doi-asserted-by":"crossref","unstructured":"Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;125:1344-1353. https:\/\/doi.org\/10.1016\/j.jaci.2010.04.004","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"10.14639\/0392-100X-N1614_ref57","doi-asserted-by":"crossref","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting >\u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-2127. https:\/\/doi.org\/10.1016\/S0140-6736(16)31324-1","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"10.14639\/0392-100X-N1614_ref58","doi-asserted-by":"crossref","unstructured":"FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as addon treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-2141. https:\/\/doi.org\/10.1016\/S0140-6736(16)31322-8","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"10.14639\/0392-100X-N1614_ref59","unstructured":"Canonica GW, Harrison TW, Chanez P, et al. Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. Abstracts from the European Academy of Allergy and Clinical Immunology Digital Congress, 06-08 June 2020."},{"key":"10.14639\/0392-100X-N1614_ref60","doi-asserted-by":"crossref","unstructured":"Bagnasco D, Brussino L, Bonavia M, et al. Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med 2020;171:106080. https:\/\/doi.org\/10.1016\/j.rmed.2020.106080","DOI":"10.1016\/j.rmed.2020.106080"},{"key":"10.14639\/0392-100X-N1614_ref61","doi-asserted-by":"crossref","unstructured":"Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy 2021;51:836-844. https:\/\/doi.org\/10.1111\/cea.13852","DOI":"10.1111\/cea.13852"},{"key":"10.14639\/0392-100X-N1614_ref62","unstructured":"Clinicaltrials.gov. Efficacy and safety study of benralizumab for patients with severe nasal polyposis (OSTRO). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03401229"},{"key":"10.14639\/0392-100X-N1614_ref63","unstructured":"Clinicaltrials.gov. Efficacy and safety study of benralizumab in patient with eosinophilic chronic rhinosinusitis with nasal polyps (ORCHID). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04157335"},{"key":"10.14639\/0392-100X-N1614_ref64","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019;74:2312-2319. https:\/\/doi.org\/10.1111\/all.13875","DOI":"10.1111\/all.13875"},{"key":"10.14639\/0392-100X-N1614_ref65","doi-asserted-by":"crossref","unstructured":"De Corso E, Kar M, Cantone E, et al. Facial pain: sinus or not? Acta Otorhinolaryngol Ital 2018;38:485-496. https:\/\/doi.org\/10.14639\/0392-100X-1721","DOI":"10.14639\/0392-100X-1721"},{"key":"10.14639\/0392-100X-N1614_ref66","doi-asserted-by":"crossref","unstructured":"Bourdin A, Adcock I, Berger P, et al. How can we minimise the use of regular oral corticosteroids in asthma? Eur Respir Rev 2020;29:190085. https:\/\/doi.org\/10.1183\/16000617.0085-2019","DOI":"10.1183\/16000617.0085-2019"},{"key":"10.14639\/0392-100X-N1614_ref67","doi-asserted-by":"crossref","unstructured":"Hopkins C, Gillett S, Slack R, et al. Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngol 2009;34:447-454. https:\/\/doi.org\/10.1111\/j.1749-4486.2009.01995.x","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"10.14639\/0392-100X-N1614_ref68","doi-asserted-by":"crossref","unstructured":"Rudmik L, Hopkins C, Peters A, et al. Patient-reported outcome measures for adult chronic rhinosinusitis: a systematic review and quality assessment. J Allergy Clin Immunol 2015;136:1532-1540.e2. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.012","DOI":"10.1016\/j.jaci.2015.10.012"},{"key":"10.14639\/0392-100X-N1614_ref69","doi-asserted-by":"crossref","unstructured":"Lund VJ, Kennedy DW. Quantification for staging sinusitis. Ann Otol Rhinol Laryngol Suppl 1995;167:17-21. https:\/\/doi.org\/10.1177\/000348949510410s02","DOI":"10.1177\/000348949510410s02"},{"key":"10.14639\/0392-100X-N1614_ref70","doi-asserted-by":"crossref","unstructured":"Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 2006;118:S17-S61. https:\/\/doi.org\/10.1016\/j.jaci.2006.09.005","DOI":"10.1016\/j.jaci.2006.09.005"},{"key":"10.14639\/0392-100X-N1614_ref71","doi-asserted-by":"crossref","unstructured":"Hopkins C, Hettige R, Soni-Jaiswal A, et al. CHronic Rhinosinusitis Outcome Measures (CHROME), developing a core outcome set for trials of interventions in chronic rhinosinusitis. Rhinology 2018;56:22-32. https:\/\/10.4193\/Rhin17.247","DOI":"10.4193\/Rhin17.247"},{"key":"10.14639\/0392-100X-N1614_ref72","doi-asserted-by":"crossref","unstructured":"Joseph T, Auger SD, Peress L, et al. Screening performance of abbreviated versions of the UPSIT smell test. J Neurol 2019;266:1897-1906. https:\/\/doi.org\/10.1007\/s00415-019-09340-x","DOI":"10.1007\/s00415-019-09340-x"},{"key":"10.14639\/0392-100X-N1614_ref73","doi-asserted-by":"crossref","unstructured":"Hummel T, Sekinger B, Wolf SR, et al. \u2018Sniffin\u2019 sticks\u2019: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 1997;22:39-52. https:\/\/doi.org\/10.1093\/chemse\/22.1.39","DOI":"10.1093\/chemse\/22.1.39"},{"key":"10.14639\/0392-100X-N1614_ref74","doi-asserted-by":"crossref","unstructured":"Oleszkiewicz A, Schriever VA, Croy I, et al. Updated Sniffin\u2019 Sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol 2019;276:719-728. https:\/\/doi.org\/10.1007\/s00405-018-5248-1","DOI":"10.1007\/s00405-018-5248-1"},{"key":"10.14639\/0392-100X-N1614_ref75","doi-asserted-by":"crossref","unstructured":"Ara\u00fajo-Martins J, Br\u00e1s-Geraldes C, Neuparth N. The potential role of peak nasal inspiratory flow to evaluate active sinonasal inflammation and disease severity. Sci Rep 2020;10:12674. https:\/\/doi.org\/10.1038\/s41598-020-69693-6","DOI":"10.1038\/s41598-020-69693-6"},{"key":"10.14639\/0392-100X-N1614_ref76","doi-asserted-by":"crossref","unstructured":"Li KL, Fang CH, Ferastraoaru D, et al. Patient satisfaction and efficiency benefits of a novel multidisciplinary rhinology and allergy clinic. Ann Otol Rhinol Laryngol 2020;129:699-706. https:\/\/doi.org\/10.1177\/0003489420905859","DOI":"10.1177\/0003489420905859"},{"key":"10.14639\/0392-100X-N1614_ref77","doi-asserted-by":"crossref","unstructured":"Canonica GW, Malvezzi L, Blasi F, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med 2020;166:105947. https:\/\/doi.org\/10.1016\/j.rmed.2020.105947","DOI":"10.1016\/j.waojou.2020.100379"},{"key":"10.14639\/0392-100X-N1614_ref78","doi-asserted-by":"crossref","unstructured":"Snidvongs K, Pratt E, Chin D, et al. Corticosteroid nasal irrigations after endoscopic sinus surgery in the management of chronic rhinosinusitis. Int Forum Allergy Rhinol 2012;2:415-421. https:\/\/doi.org\/10.1002\/alr.21047","DOI":"10.1002\/alr.21047"},{"key":"10.14639\/0392-100X-N1614_ref79","doi-asserted-by":"crossref","unstructured":"Snidvongs K, Kalish L, Sacks R, et al. Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis: systematic review and meta-analysis. Am J Rhinol Allergy 2013;27:221-233. https:\/\/doi.org\/10.2500\/ajra.2013.27.3880","DOI":"10.2500\/ajra.2013.27.3880"},{"key":"10.14639\/0392-100X-N1614_ref80","doi-asserted-by":"crossref","unstructured":"Nakayama T, Asaka D, Kanaya H, et al. Prognostic factors for recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Auris Nasus Larynx 2016;43:641-647. https:\/\/doi.org\/10.1016\/j.anl.2016.02.015","DOI":"10.1016\/j.anl.2016.02.015"},{"key":"10.14639\/0392-100X-N1614_ref81","doi-asserted-by":"crossref","unstructured":"Wu CL, Lee TJ, Huang CC, et al. Clinical predictors of revision surgery for chronic rhinosinusitis with nasal polyposis within 5-year follow-up. Am J Otolaryngol 2020;41:102654. https:\/\/doi.org\/10.1016\/j.amjoto.2020.102654","DOI":"10.1016\/j.amjoto.2020.102654"},{"key":"10.14639\/0392-100X-N1614_ref82","doi-asserted-by":"crossref","unstructured":"Amedee RG. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Am J Rhinol Allergy 2017;31:278. https:\/\/doi.org\/10.2500\/194589217821335822","DOI":"10.2500\/194589217821335822"},{"key":"10.14639\/0392-100X-N1614_ref83","doi-asserted-by":"crossref","unstructured":"Alsharif S, Jonstam K, van Zele T, et al. Endoscopic sinus surgery for type-2 CRS wNP: an endotype-based retrospective study. Laryngoscope 2019;129:1286-1292. https:\/\/doi.org\/10.1002\/lary.27815","DOI":"10.1002\/lary.27815"},{"key":"10.14639\/0392-100X-N1614_ref84","doi-asserted-by":"crossref","unstructured":"Hopkins C, Lund V. Does time from previous surgery predict subsequent treatment failure in chronic rhinosinusitis with nasal polyps? Rhinology 2021;59:277-283. https:\/\/doi.org\/10.4193\/Rhin21.017","DOI":"10.4193\/Rhin21.017"},{"key":"10.14639\/0392-100X-N1614_ref85","doi-asserted-by":"crossref","unstructured":"Bhattacharyya N, Villeneuve S, Joish VN, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 2019;129:1969-1975. http:\/\/doi.org\/10.1002\/lary.27852","DOI":"10.1002\/lary.27852"},{"key":"10.14639\/0392-100X-N1614_ref86","doi-asserted-by":"crossref","unstructured":"Roland LT, Smith TL, Schlosser RJ, et al. Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health\u2013sponsored workshop. Int Forum Allergy Rhinol 2020;10:1037-1042. https:\/\/doi.org\/10.1002\/alr.22633","DOI":"10.1002\/alr.22633"},{"key":"10.14639\/0392-100X-N1614_ref87","doi-asserted-by":"crossref","unstructured":"Gurrola J II, Borish L. Chronic rhinosinusitis: endotypes, biomarkers, and treatment response. J Allergy Clin Immunol 2017;140:1499-1508. https:\/\/doi.org\/10.1016\/j.jaci.2017.10.006","DOI":"10.1016\/j.jaci.2017.10.006"},{"key":"10.14639\/0392-100X-N1614_ref88","doi-asserted-by":"crossref","unstructured":"Brown WC, Senior B. A critical look at the efficacy and costs of biologic therapy for chronic rhinosinusitis with nasal polyposis. Curr Allergy Asthma Rep 2020;20:16. https:\/\/doi.org\/10.1007\/s11882-020-00910-y","DOI":"10.1007\/s11882-020-00910-y"},{"key":"10.14639\/0392-100X-N1614_ref89","doi-asserted-by":"crossref","unstructured":"Anderson WC, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol 2019;122:367-372. https:\/\/doi.org\/10.1016\/j.anai.2019.01.018","DOI":"10.1016\/j.anai.2019.01.018"},{"key":"10.14639\/0392-100X-N1614_ref90","doi-asserted-by":"crossref","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol 2017;118:220-225. https:\/\/doi.org\/10.1016\/j.anai.2016.10.028","DOI":"10.1016\/j.anai.2016.10.028"},{"key":"10.14639\/0392-100X-N1614_ref91","doi-asserted-by":"crossref","unstructured":"Lam J, Hay JW, Salcedo J, et al. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma 2019;56:872-881. https:\/\/doi.org\/10.1080\/02770903.2018.1500584","DOI":"10.1080\/02770903.2018.1500584"},{"key":"10.14639\/0392-100X-N1614_ref92","doi-asserted-by":"crossref","unstructured":"Tice JA, Campbell JD, Synnott PG, et al. The effectiveness and value of biologic therapies for the treatment of uncontrolled asthma. J Manag Care Spec Pharm 2019;25:510-514. https\/\/doi.org\/10.18553\/jmcp.2019.25.5.510","DOI":"10.18553\/jmcp.2019.25.5.510"},{"key":"10.14639\/0392-100X-N1614_ref93","doi-asserted-by":"crossref","unstructured":"Blackwell DL, Collins JG, Coles R. Summary health statistics for U.S. adults: National Health Interview Survey, 1997. Vital Health Stat 2002;10:1-109.","DOI":"10.1037\/e609492007-001"},{"key":"10.14639\/0392-100X-N1614_ref94","doi-asserted-by":"crossref","unstructured":"Rudmik L, Soler ZM, Smith TL, et al. Effect of continued medical therapy on productivity costs for refractory chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg 2015;141:969-973. https:\/\/doi.org\/10.1001\/jamaoto.2015.2321","DOI":"10.1001\/jamaoto.2015.2321"},{"key":"10.14639\/0392-100X-N1614_ref95","doi-asserted-by":"crossref","unstructured":"Rudmik L, Smith TL, Mace JC, et al. Productivity costs decrease after endoscopic sinus surgery for refractory chronic rhinosinusitis. Laryngoscope 2016;126:570-574. https:\/\/doi.org\/10.1002\/lary.25656","DOI":"10.1002\/lary.25656"},{"key":"10.14639\/0392-100X-N1614_ref96","doi-asserted-by":"crossref","unstructured":"Luk LJ, Steele TO, Mace JC, et al. Health utility outcomes in patients undergoing medical management for chronic rhinosinusitis: a prospective multiinstitutional study. Int Forum Allergy Rhinol 2015;5:1018-1027. https:\/\/doi.org\/10.1002\/alr.21588","DOI":"10.1002\/alr.21588"},{"key":"10.14639\/0392-100X-N1614_ref97","doi-asserted-by":"crossref","unstructured":"Beswick DM, Mace JC, Rudmik L, et al. Productivity changes following medical and surgical treatment of chronic rhinosinusitis by symptom domain. Int Forum Allergy Rhinol 2018;8:1395-1405. https:\/\/doi.org\/10.1002\/alr.22191","DOI":"10.1002\/alr.22191"},{"key":"10.14639\/0392-100X-N1614_ref98","doi-asserted-by":"crossref","unstructured":"Chowdhury NI, Mace JC, Smith TL, et al. What drives productivity loss in chronic rhinosinusitis? A SNOT-22 subdomain analysis. Laryngoscope 2018;128:23-30. https:\/\/doi.org\/10.1002\/lary.26723","DOI":"10.1002\/lary.26723"}],"container-title":["Acta Otorhinolaryngologica Italica"],"original-title":[],"link":[{"URL":"https:\/\/www.actaitalica.it\/article\/view\/1614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T07:19:12Z","timestamp":1729667952000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.actaitalica.it\/article\/view\/1614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2]]}},"URL":"https:\/\/doi.org\/10.14639\/0392-100x-n1614","relation":{},"ISSN":["1827-675X"],"issn-type":[{"value":"1827-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"article-number":"1"}}